Eloxx Pharmaceuticals has dosed the first two patients in its Phase 2b EXACT study testing exaluren for nonsense mutation Alport syndrome (NMAS), a rare genetic kidney disease with no FDA-approved treatments. The trial will evaluate the drug's safety and efficacy in 24 patients, with topline data from the initial 16-week placebo-controlled phase expected by mid-2027 and final results by the end of 2027. Exaluren aims to address the genetic cause by promoting production of functional protein, offering hope for patients who often face kidney failure by their twenties.
The global hot water boilers market is projected to grow from $31.5 billion in 2026 to $51.31 billion by 2036, at a 5% CAGR. Growth is fueled by demand for energy-efficient heating, modernization of infrastructure, and integration of smart controls. ...
The global textile recycling market is projected to grow from $6.4 billion in 2026 to $14.2 billion by 2036, at a CAGR of 7.5%. Growth is fueled by regulatory pressures like EPR mandates, corporate recycled-content targets, and investments in circula...
The global semiconductor ultrapure water systems market is projected to grow from USD 2.2 billion in 2026 to USD 4.7 billion by 2036, at an 8.0% CAGR. Growth is fueled by expanding semiconductor fabrication capacity, stricter water purity needs for a...
The global hidden deck fastener market is projected to grow from $568.8 million in 2026 to $789.1 million by 2033, at a CAGR of 4.8%. This growth is fueled by increasing demand for premium decking systems that offer better aesthetics, durability, and...
ISS A/S is actively executing its share buyback programme announced in February 2026, aiming to redistribute excess cash to shareholders by reducing share capital and fulfilling share-based incentive obligations. The company has repurchased shares wo...
